Clinical effects of short-term oral budesonide on the hypothalamic-pituitary-adrenal axis in dogs with inflammatory bowel disease.
Six dogs were entered into a 30-day, prospective, nonrandomized, uncontrolled clinical trial evaluating the effects of an oral preparation of budesonide on the hypothalamic-pituitary-adrenal (HPA) axis during therapeutic management of active inflammatory bowel disease. Oral budesonide, at a dose of 3 mg/m(2), was administered once daily. Upon entry and completion of the trial, serum basal cortisol, adrenocorticotropic (ACTH)-stimulated cortisol, endogenous ACTH concentration, serum alkaline phosphatase (SAP) activity, and urine specific gravity were evaluated, as well as owner assessment of glucocorticoid-associated side effects. Significant suppression of the HPA axis occurred. No significant differences in SAP activity, urine specific gravity, or owner-subjective assessments were detected.
The Animal Medical Center, E & M Bobst Hospital, Caspary Research Institute, New York, New York 10021-8314, USA.
Joshua W
JW
Tumulty
John D
JD
Broussard
Jörg M
JM
Steiner
Mark E
ME
Peterson
David A
DA
Williams
D000324:Adrenocorticotropic Hormone / Q000097:blood; D000469:Alkaline Phosphatase / Q000378:metabolism; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000494:pharmacology*; D019819:Budesonide / Q000009:adverse effects / Q000494:pharmacology*; D004283:Dog Diseases / Q000097:blood / Q000188:drug therapy*; D004285:Dogs; D006854:Hydrocortisone / Q000097:blood; D015212:Inflammatory Bowel Diseases / Q000097:blood / Q000188:drug therapy*; D010912:Pituitary-Adrenal Function Tests / Q000662:veterinary*; D010913:Pituitary-Adrenal System / Q000187:drug effects*; D011446:Prospective Studies; D016896:Treatment Outcome; D016482:Urinalysis / Q000379:methods / Q000662:veterinary
D000893:Anti-Inflammatory Agents; D019819:Budesonide; D000324:Adrenocorticotropic Hormone; D000469:Alkaline Phosphatase; D006854:Hydrocortisone